OTC Denavir Advisory Cmte. Members Uncomfortable With Risk/Benefit Ratio

A joint FDA advisory committee recommended against the Rx-to-OTC switch of SmithKline Beecham's Denavir in a narrow vote, with several members questioning whether the potential risks from broader access to the 1% penciclovir cream for cold sores may outweigh its benefits.